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Objective: Randomized controlled trials (RCTs) of carotid endarterectomy (CEA) advised little benefit from surgery in
women because of high operative risk. Whether these findings are also applicable to carotid angioplasty and stenting
(CAS) is subject of investigation. Our aimwas to determine the risk of perioperative and late complications related to CAS
and CEA in women.
Methods: Data from a single-center carotid surgery database including 1065 individuals with CAS (306 women and 759
men) and 1131 with CEA (325 women and 806men) were analyzed in a consecutive series of patients. Perioperative risks
of death, stroke, and local complications in women undergoing CAS and CEA were compared. Rates of restenosis >50%
and stroke at 5 years in symptomatic and asymptomatic women were also assessed.
Results: The perioperative risks of stroke or death were no different in women who underwent CAS and CEA women
(1.9% vs 3.0%; odds ratio [OR] 0.63; 95% confidence interval [CI], 0.20-1.7; P .45) whether they were symptomatic
or not. Other perioperative complications were also similarly distributed between the two groups of women. Life-table
estimates of any periprocedural stroke/death and ipsilateral stroke at 5 years after the procedure did not differ between
women with CAS and CEA (4.1% vs 8.1%; P  .18). Five-year rates of restenosis >50% were nonsignificantly higher in
women after CEA than after CAS (1.8% vs 8.1%; P  .058).
Conclusion: Women with carotid stenosis might have favorable early and late outcomes from CAS with complication rates
similar and even lower than those attained with CEA. CAS, performed by trained operators, may be a valid primary choice for
treatment of carotid stenosis, particularly in asymptomatic women for whom the risk of surgery seems to be higher. However,
before claiming CAS for women, these results need to be confirmed by large RCTs. (J Vasc Surg 2010;51:337-44.)The clinical and public health impact of stroke on women
has gained increasing relevance during recent years in terms of
worse outcomes (higher lethality, disability, and poor quality
of life in women after a stroke) and larger prevalence due to
the increased life expectancy of female gender.1
In addition, benefit of preventive treatments may be
consistently poorer in women than in men.2-7 Female
gender has been identified as a potential factor affecting
poor perioperative stroke and death rates associated with
carotid endarterectomy (CEA), the “gold standard” treat-
ment for patients with severe carotid disease. In patients
with carotid stenosis, gender differences in treatment out-
come have been reported in all large randomized controlled
trials (RCT) comparing best medical therapy to CEA.2-7
Women with symptomatic or asymptomatic carotid steno-
sis were shown to have a high operative risk during CEA
but a low risk of neurologic events when treated with
medical therapy alone.3,5,6 Therefore, the benefit from
CEA (highly effective in preventing strokes in male pa-
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doi:10.1016/j.jvs.2009.08.095tients) is still questionable in females, and doubts about
advantages of carotid revascularization have been raised.1-5
Carotid angioplasty stenting (CAS) was developed to
be a less invasive alternative for carotid artery revasculariza-
tion in “high-risk” surgery patients. Recently published
RCTs questioned the benefit of CAS mainly in patients
with symptomatic carotid stenosis.8,9 Nevertheless, the
benefit of CAS in specific subgroups of patients with carotid
stenosis, particularly females and asymptomatics, is still
unclear.8,9
While based on CEA RCT data, most women might be
assumed to be “high-risk” surgery patients,3,5,6 mainly for
the high perioperative hazard; whether similar concerns
regarding the unfavorable risk-to-benefit stroke ratio in
women after CEA are also applicable to CAS remains a
subject of investigation.
Therefore, the aim of this study was to analyze peripro-
cedural risks and long-term durability of carotid revascular-
ization in women after CAS and CEA procedures.
MATERIALS AND METHODS
Patients in a prospectively compiled computerized da-
tabase of all primary extracranial carotid revascularizations
(CAS and CEA) performed at a single center from January
1, 2004, to January 1, 2009, with 60% symptomatic or
70% asymptomatic carotid stenosis were reviewed. The
revascularization treatment choice (CAS/CEA) was left to
the discretion of the treating surgeon according to peripro-
cedural risk evaluation, such as plaque and vessel morphol-
ogy, neurologic status, and comorbidities. Although, after
the learning curve phase, CAS was more widely applied also
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tions similar to CEA, there was a higher preference for CAS
in patients with comorbidities such as coronary or respira-
tory disease or contralateral occlusion. Conversely, lessons
from the learning curve experience of CAS allowed us to
favor CEA in the elderly and in patients with hypoechoic or
strongly calcified carotid plaque at ultrasound scan evalua-
tion or difficult access (peripheral artery disease). For the
purpose of the study, patients who underwent revascular-
ization for recurrent carotid stenosis and bypass grafts were
excluded.
To avoid bias due to the learning curve effect of the
operators, patients with CAS performed within the training
phase (2001-2003 interval) were excluded. According to
our experience, the caseload necessary to perform safe CAS
(assuming 2% as the safety threshold/year for major
periprocedural complication rate) included the first 195
procedures. It was after this training (collected in the same
group of operators who also performed procedures in the
following years) that the rate of disabling strokes (mainly
occurring during the most challenging phases of the CAS
procedure such as catheterization, requiring expert skills)
significantly decreased and remained stable at2% for each
of the following years (2004). These data have been
published in previous reports.10,11
CAS was carried out following a standardized protocol
in an endovascular room equipped with a high-quality fixed
imaging system (Axiom Artis FA; Siemens, Erlangen, Ger-
many). On-table rotational angiography was used in se-
lected cases to better visualize the stenosis and to select the
optimal working projection.
Percutaneous transfemoral or transbrachial approaches
under local anesthesia were used. Neurologic status was
continuously monitored, and transcranial Doppler (TCD
4040 Pyoneer EME) monitoring was used when possible.
Intravenous heparin (100 U/kg) was given routinely be-
fore selective catheterization of the common carotid artery
(CCA) and not reversed at the end of the procedure.
All procedures were performed with cerebral protec-
tion devices (CPD) and different stent models (open cell,
close cell, or hybrid configuration [tapered or straight]).
The choice of specific material depended on vessel anatomy
and lesion characteristics. CPDs were proximal occlusion
devices: (n  16, 5.2%) MO.MA System (Invatec,
Roncadelle, Italy) or distal filters: (n 290) FilterWire EZ
system (Boston Scientific, Natick, Mass) (n 225, 73.5%);
Angioguard RX Filter (Johnson and Johnson-Cordis, War-
ren, NJ) (n  27, 8.8%); Emboshield Filter (Abbott Lab-
oratories, Abbott Park, Ill) (n  27, 8.8%); Rx Accunet
Filter (Guidant, Santa Clara, Calif) (n 4, 1.3%); Rubicon
Filter (Rubicon Medical Inc, Salt Lake City, Utah) (n 1,
0.3%); SpideRX Filter (EV3, Plymouth, Minn) (n  6,
1.9%).
Self-expandable stents were close-cell design/elgiloy
fabric in 180 cases (58.8%) (n  157 Carotid Wallstents,
Boston Scientific Corp, Natick, Mass); (n  23) Xact
(Abbott Vascular Devices, Redwood City, Calif) and
open cell/nitinol made in 126 (41.2%; n  91) Precisestents (Johnson and Johnson-Cordis) (n 11) PROTEGE
Rx Stent System (EV3), (n  8) Acculink (Guidant); and
(n  16) multidesigned Cristallo Ideale (Invatec).
Stent size and length were chosen according to preop-
erative measurements of the target vessel by Doppler ultra-
sound scan examination. Closure devices for the access
control have been used since 2006.
Consecutive primary CEAs performed from January
2001 to August 2007 were included in the analysis. CEAs
performed in the last 2 years (2007-2008) were excluded to
avoid possible selection bias because of the increasing trend
to perform CAS as a primary choice in most patients,
restricting CEA to a minority and most hazardous cases in
the more recent period.
CEA was performed under local or general anesthesia.
A shunt was used selectively according to clamping intol-
erance. Eversion or patch and occasionally direct closure
were used. Patient monitoring followed the same modality
as CAS in awake patients; TCD flow velocity or stump
pressure measurements were used when general anesthesia
was employed. Systemic heparinization was used at the
same dosage as CAS and then reversed after carotid
declamping.
Patient evaluation. Features and time of preoperative
symptoms were evaluated by external neurologic audit.
Patients were defined symptomatic when ipsilateral hemi-
spheric or retinal symptoms occurred within 6months from
the procedure.
The degree and characteristics of carotid stenosis at
baseline and during follow-up were assessed with duplex
ultrasound scan by experienced operators who defined site,
degree, length of stenosis, plaque characteristics, and vessel
measurements previously validated against angiography as a
gold standard technique. Two carotid measurements were
additionally recorded by ultrasound scan before CAS: CCA
(2 cm below the bulb) and internal carotid diameter (ICA 2
cm above the carotid bulb, or in case of longer plaques
distal to the plaque end). In the group of patients with
CEA, we did not take specific carotid vessel diameter mea-
surements. Carotid plaque was defined as “complex
plaque” according to the duplex ultrasound scan appear-
ance of prevalence of hypoechoic pattern (suggesting for
presence of hemorrhage, thrombus, and fatty tissues).
However, in CEA, morphologic assessment was confirmed
by intraoperative macroscopic evaluation.
Contrast-enhanced computed tomography (CTA) was
performed selectively, in case of uncertainty at ultrasound
scan examination. The degree of stenosis was always con-
firmed by visual evaluation with angiography during CAS.
Cerebral CT scan was used in symptomatic patients to
assess the extent of recent lesions if any.
Patients scheduled for CAS received antiplatelet ther-
apy consisting of acetylsalicylic acid (mean dosage 125
mg/die) and clopidogrel (75 mg/die) for at least 30 days
after a 300-mg leading dose administered 12 hours before
CAS. In patients who underwent CEA, single antiplatelet
medication was not discontinued for surgery. Written con-
sent was obtained from all patients before revascularization.
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uled at 6months, 12months, and yearly thereafter. Carotid
restenosis was set at 50%. Patients were instructed to
report any new neurologic symptoms occurring after hos-
pital discharge. When neurologic symptoms or uncertainty
occurred anytime after the procedure, patients were evalu-
ated by a certified neurologist expert in vascular disease.
Outcome measures. Stroke was defined as any new
hemispheric or retinal neurologic event persisting 24
hours and classified as fatal, disabling (modified Rankin
Score 3), or nondisabling (modified Rankin Score 3).
Myocardial infarction (MI) was diagnosed by the cardiolo-
gist in the occurrence of persistent ST segment changes on
electrocardiogram and/or new Q wave in two leads or the
presence of elevated enzymes (including troponin 0.1
ng/mL).
Primary outcome was the combined risk of any stroke
or death within 30 days. Secondary outcomes were any
stroke, disabling stroke, transient ischemic attack (TIA),
MI, and local complications (hematoma or nerve palsy)
occurring within 30 days. Late outcomes included the
combined endpoint of ipsilateral stroke after the procedure
plus any periprocedural stroke or death, and the rate of any
stroke, death, and restenosis after the procedure.
Statistical analysis. In assessing outcome, patients
were analyzed according to the treatment they received
(on-treatment analysis). Patients who were scheduled for
CAS, and eventually converted to CEA because of CAS
failure, were analyzed according to the treatment they
actually received.
Tests of statistical significance comparing women and
men were conducted using 2 and Fisher’s exact test for
categoric variables, analysis of variance (ANOVA), and t
test for continuous variables. Unadjusted and adjusted
odds ratios (ORs) with correspondent 95% confidence
intervals (CIs) were used to compare outcomes between
genders.
The association between demographic, clinical, and
procedural characteristics, and the combined periproce-
dural (within 30 days) risk of any stroke or death was first
assessed by univariate logistic method. Analyses were strat-
ified by preoperative symptoms to compensate for evident
differences in symptomatic and asymptomatic distribution
of patients.
Multivariable logistic regression analyses using back-
ward elimination methods were performed to adjust for
potential confounders including age, CAS vs CEA proce-
dure, preoperative symptoms, contralateral occlusion, cor-
onary disease, peripheral artery disease, diabetes, hyperten-
sion, history of hyperlipemia requiring statin therapy, and
“complex” carotid plaque. Sensitivity analyses were per-
formed to adjust for technical details used in each CAS or
CEA group. Interactions among the covariates and female
gender were assessed in models stratified by CAS or CEA in
which procedure-specific technical factors were tested (in
CEA analysis: anesthesia, shunt, primary closure; in CAS
analysis: open vs close cell design of the stent, occlusion vs
filter cerebral protection device model). Results from mul-tivariate analysis are presented as hazard ratios (HRs) with
95% CIs.
The rates of endpoints at 5 years were estimated with
the Kaplan-Meier method to compensate for patient drop-
outs, and the level of significance was calculated with
log-rank test and its SE. The Kaplan-Meier curves were
computed for symptomatic and asymptomatic patients us-
ing stroke as an endpoint (late ipsilateral stroke and any
periprocedural stroke/death). Curves were displayed up to
a value of SE 0.10%. For all tests, a probability value of
P  .05 was considered statistically significant. Stat-Calc-
EPIINFO 6.0/PC v 3.5.1 and SPSS/PC v 13.00 Win
package (SPSS for Windows, Chicago, Ill, 2003) were used
for all data analyses.
RESULTS
Over the study period, a total of 2196 interventions for
primary carotid stenosis were performed in 1951 patients:
1065 CAS (in 971 patients) and 1131 CEA (in 980 pa-
tients).
A total of 306 CAS were performed in 282 women and
759 CAS were performed in 689 men. Three hundred
twenty-five CEAs were performed in 285 woman and 806
in 695 men.
Comparison between women who underwent
CAS and CEA. Demographic and baseline data for the
CAS and CEA groups are displayed in Table I.
A greater number of asymptomatic women were
treated with CAS (78.8% vs 67.7%, in CAS and CEA,
respectively; P  .002) due to a higher preference to
perform CEA in the presence of “complex”/hypoechoic
carotid plaque (34.5% vs 26.8% in CEA and CAS, respec-
tively; P .04). CAS was less likely in women with difficult
endoluminal access to carotid vessels for the presence of
peripheral vascular disease (7.4% vs 12.6% in CAS andCEA,
respectively; P  .035). Women who underwent CEA
compared to those who underwent CAS were less likely to
present contralateral carotid occlusion (2.8% vs 6.4%; P 
.002), history of hyperlipidemia (54.7% vs 64%; P  .02)
and coronary disease (22.8% vs 31.6%; P  .02).
Periprocedural outcomes. Six women failed CAS
(procedure success rate 98%) because of impossibility to
approach or cross the carotid lesion (n  5) or because of
acute stent thrombosis (n 1) andwere converted to CEA.
In one of these women, a mild arm and leg deficit devel-
oped after CAS due to incomplete carotid plaque coverage
by stenting (plaque protrusion through stent struts). Neu-
rologic deficit resolved completely after conversion to
CEA. No other complications occurred among women
converted to CEA with the exception of one neck hema-
toma. There was no technical failure in the CEA group of
women who underwent CEA.
There were no significant overall differences in periop-
erative outcomes between women who underwent CAS
and CEA. No deaths occurred in the CAS group, while 2
women died after CEA, 1; one patient died from cardiac
complications and the other for fatal stroke. The risk of
periprocedural stroke or death was slightly lower in the
odds
in CEA
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vs 3.0%; P  .45; Table II). The tendency toward a lower
risk in CAS women who underwent CAS was more evident
in the asymptomatic subgroup (1.2% vs 3.2%; P  .2). In
the symptomatic subgroup of women, stroke risk was non-
significantly higher in CAS: 4.6% vs 1.9%; P  .37. Other
outcome measures in the CAS group compared to women
who underwent CEA are reported in Table II. Distribution
of minor neurologic events (3.2% vs 1.2%; P .1) and local
hematoma (1.6% vs 2.8%; P  .8) were higher in women
who underwent CAS, even though not significantly different
from those in the CEA group. There was a higher rate of
major adverse cardiac events (MACEs) (2.3% vs 3.7% in CAS
vs CEA; P .35) and nerve palsy in CEA women population
(0.5% vs 1.9% in CAS vs CEA, respectively; P .25).
Univariate analysis demonstrated that the only factor
significantly associated with a periprocedural stroke or
death risk in women was history of hyperlipemia requiring
statin therapy (OR, 0.30; 95% CI, 0.10-0.88; P .036). In
Table I. Baseline characteristics of 631 women in CAS vs
CAS group
(n  306) n (%)
Baseline characteristics
Age (mean [range]) 71.18 7.6 (46-87) 7
Hypertension 264 86.2 2
Diabetes 87 28.4
Peripheral artery disease 23 7.4
History of hyperlipemia 196 64.0 1
Coronary disease 97 31.6
Contralateral occlusion 21 6.4
Symptomatic 65 21.2 1
Previous TIA 34
Previous stroke 31
Complex plaque* 82 26.8 1
Bilateral procedure 24 7.8
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy; OR,
*Complex plaque was defined macroscopically at intraoperative evaluation
Table II. Outcomes at 30 days in 631 women after CAS
CAS group
(n  306) n (%)
30-day outcomes
Death or stroke 6 1.9
Stroke 6 1.9
Stroke in asymptomatic 3/241 1.2
Disabling stroke in asymptomatic 0/241
Stroke in symptomatic 3/65 4.6
Disabling stroke in symptomatic 2/65
Disabling stroke 2 0.65
Death — —
TIA 10 3.2
Myocardial infarction 2 0.65
MACE 7 2.3
Hematoma 5 1.6
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy; OR,
adverse clinical event (stroke/death/myocardial infarction).multivariable logistic regression analysis after adjusting forconfounding factors, the history of hyperlipidemia requir-
ing use of statins (HR, 0.3; 95% CI, 0.10-0.88; P  .028)
was confirmed as the only negative predictor for the pri-
mary outcome. Multivariable analyses stratified by proce-
dure and adjusting also for technical details (anesthesia,
shunt, patch in CEA, open cell stent, occlusion vs filter
protection device for CAS) failed to show any significant
predictor in both the subgroup of females who underwent
CAS and CEA.
Late outcomes. Mean follow-up was 22.8  19
months (range, 1-60 months) in the CAS group and
24.5  19 (range, 1-74 months) in the CEA group of
women. During the observation period, 27 females died,
n  17 after CAS, n  10 after CEA. In the CAS group,
two fatal strokes (one hemorrhagic), seven cancer, and
eight cardiac deaths occurred; in the CEA group, there
were three fatal strokes (one hemorrhagic), two cancer, and
five cardiac deaths. Kaplan-Meier survival analysis showed
no difference in 5-year survival between the CAS and CEA
A group
325) n (%) OR 95% CI P value
7.6 (48-87) .8
83.3 1.25 0.89-1.9 .32
28.9 1.02 0.79-1.3 .93
12.6 0.56 0.32-0.96 .035
54.7 1.47 1.07-2.03 .019
22.8 1.57 1.10-2.23 .015
2.8 2.58 1.16-5.7 .023
32.3 0.56 0.39-0.80 .002
34.5 0.69 0.49-0.97 .04
12.3 0.58 0.33-1.02 .06
ratio; CI, confidence interval; TIA, transient ischemic attack.
and according with duplex scan in CAS.
A
CEA group
n  325) n (%) OR 95% CI P value
10 3 0.63 0.2-1.7 .45
9 2.7 0.7 0.2-1.9 .6
220 3.2 0.38 0.09-1.5 .2
220 0.0-35.6 .47
105 1.9 2.49 0.28-30.43 .37
105 1.08 0.12-8.2 1
3 0.9 0.7 0.11-4.2 1
2 0.6 — — .5
4 1.23 2.7 0.84-8.7 .1
3 0.9 0.7 0.11-4.25 1
12 3.7 0.61 0.24-1.57 .35
9 2.8 0.76 0.23-2.54 .8




















odds rgroups (86.4% vs 91.2%; P  .11; Fig 1). The incidence of
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equally distributed in CAS and CEA populations. Six of
these strokes were ipsilateral to the treated carotid (one in
CAS and five in CEA). There were no differences at 5 years
after the procedure in Kaplan-Meier estimates of ipsilateral
stroke and any periprocedural stroke or death between the
CAS and CEA groups (4.1% vs 8.1; P .18; Fig 2). In both
the symptomatic and asymptomatic patients, estimates
were similar between women who underwent CAS and
CEA (for symptomatic females: 5.2% vs 7.9%; P  .57; for
asymptomatic females 2.8% vs 3.8% in the CAS and CEA
groups, respectively; P .44). During follow-up, recurrent
stenosis of 50% or more was detected in 17 female patients
(5 after CAS and 12 after CEA). Kaplan-Meier analysis
revealed no significant difference between women in the
CAS and CEA groups in the restenosis rate at 5 years (1.8%
vs 8.1% for CAS and CEA, respectively; P  .058; Fig 3).
Only four recurrent stenosis (three in the CAS group
Fig 1. Survival rates in CAS and CEA women. CAS, Carotid
angioplasty with stenting; CEA, carotid endarterectomy. Log rank
test, P  .11.
Fig 2. Probability of ipsilateral stroke plus any periprocedural
stroke or death in CAS and CEA women. CAS, Carotid angio-
plasty with stenting; CEA, carotid endarterectomy.and one in women who underwent CEA) led to neurologicsymptoms. Overall, nine reinterventions were performed,
four after CAS, and five after CEA due to symptoms or
high-grade asymptomatic restenosis.
DISCUSSION
In this study, the initial hypothesis of CAS as a more
hazardous procedure for women was not confirmed: peri-
operative stroke and death rate in women who underwent
CAS (1.9%) was low and below the recommended standard
threshold of perioperative risk for carotid revascularization
(3%). Although women who underwent CAS were a higher-
risk population (high frequency of coronary disease, hyper-
lipemia, and contralateral occlusion), perioperative and late
risks were comparable and even lower than those of women
who underwent CEA. The lack of effect of gender on CAS
outcome of this study was strengthened by logistic regres-
sion analysis providing estimates of the effect of the proce-
dure on perioperative stroke/death risk in the presence of
potential confounding factors not equally distributed be-
tween women who underwent CAS and CEA. However,
the data may still be unbalanced and underpowered to
prove equipoise between treatments and should be inter-
preted with caution. This concern is raised by the low
primary outcome rates observed in this series for women in
both the CAS and CEA groups. Specifically, 16 periproce-
dural stroke/death events occurred in 306 women who
underwent CAS and 325 who underwent CEA.
CAS was associated with low risks of periprocedural
stroke especially in asymptomatic females, in whom the
periprocedural stroke rate of CAS was less than half com-
pared to that of CEA (1.2% vs 3.2.%; OR  0.38; 95% CI,
0.09-1.5; P .2), and the risk of disabling stroke was 0.We
stratified the analysis of outcomes by symptoms, because
symptomatic and asymptomatic patients were not equally
distributed between the two female groups. Indeed, the
preference to avoid hypoechoic/complex carotid plaque
Fig 3. Probability of restenosis after the procedure in the CAS
and CEA women. CAS, Carotid angioplasty with stenting; CEA,
carotid endarterectomy. Log rank test, P  .058.during CAS allowed to a higher frequency of symptomatic
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vs 21.2%) into the group of women who underwent CEA.
Although the differences in outcomes between women
who underwent CAS and CEA did not reach statistical
significance, and selection biases could have affected the
results, the overall absolute findings may be consistent with
a safe and favorable outcome for women treated with CAS,
particularly when asymptomatic.
Other reports have suggested that the perioperative risk
related to carotid surgery (CEA) might be much higher
specifically in asymptomatic women.5,7,12 Such increased
risk was not assessed for the women in our CAS group,
suggesting a potential benefit of CAS particularly in asymp-
tomatic women in whom the risk of CEA seems to be
higher.
Conversely, our data might suggest a higher risk of
CAS with respect to CEA for symptomatic patients, al-
though no significant differences in outcomes were found.
However, we cannot provide any reliable suggestions for
symptomatic women because the numbers were small es-
pecially for CAS (n  65). Only one-fourth of the overall
female population was symptomatic (n  170), and the
power of our study was particularly low to detect the
differences between symptomatic subgroups of women
who underwent CAS and CEA.
Published RCTs on CAS in symptomatic patients
agreed on an increased risk from CAS vs CEA in symptom-
atic populations, regardless of the gender. Today, the effi-
cacy of CAS for “all-comers” is still not proven (also, the
latest International Carotid Stenting Study [ICSS] con-
firmed a two-time perioperative risk of stroke in CAS vs
CEA, 7.6% vs 3.9%, online publication), but other RCTs
are still ongoing (Carotid Revascularization Endarterec-
tomy versus Stenting Trial [CREST], Asymptomatic Ca-
rotid Surgery Trial [ACST2]) to confirm these data. In the
meantime, CAS is commonly accepted for some subgroups
of patients considered at high risk for surgery. Women, at
least some of them, may represent one of these subgroups
because of a higher risk of CEA (eg, asymptomatic fe-
males). However, before claiming CAS as the treatment of
choice for women with carotid stenosis, these hypotheses
need to be confirmed by ongoing RCTs.
Recent literature showed that CAS may be performed
with low complication rates in women, but there is no
strong evidence, also supported by RCTs, to this regard, as
the overall populations of women is limited.13-16 The
CREST lead-in study is, at present, the largest experience
analyzing gender-related outcomes of CAS (1564 patients,
576 women and 985 men) and found similar perioperative
stroke and death rates in women vs men (4.5% vs 4.2%).13
Despite the large number of patients, the overall number of
events was low (n  67 in the total population). Authors
raised concerns on the study power and calculated that the
actual power of their study to detect such small differences
was marginal (about 6%).13 An increase of up to 7.5%
(event rate females/males difference  3.0) in the event
rates in women could have been needed to provide 80%
power. However, it appears somewhat unlikely that suchgender-related differences could exist as shown in recent
literature.14,15 Goldstein et al14 in 238 CAS reported a
combined 30-day stroke, death, and MI rate of 5.7% vs
5.4% in males and females, respectively. In addition, no
differences were observed in long-term survival, stroke-free
survival, and restenosis rates. Park et al15 showed very low
perioperative stroke and death rates in women who under-
went both CAS (2%) and CEA (0%) procedures. Neverthe-
less, their sample of 100 female patients for both CAS and
CEA was too small to detect a difference.16
Even more insubstantial and also conflicting informa-
tion on the risks of CAS in women is available from pub-
lished RCTs.16-20 The stent-protected angioplasty vs ca-
rotid endarterectomy in symptomatic patients (SPACE)
trial, including 171 symptomatic women and 436 symp-
tomatic men in the CAS group, was the only RCT that
specifically analyzed the outcome in women and showed a
slightly nonsignificant increase in the primary endpoint
(ipsilateral stroke or death within 30 days) rate for symp-
tomatic women in a subgroup analysis stratified by gender
(8.2% vs 6.4%).19 The rate of ipsilateral stroke within 2
years plus periprocedural stroke and death was indeed
lower in women (8.3% vs 9.9%).20 Nevertheless, none of
these differences were significant.19,20 Very limited infor-
mation, if any, is available from the small number of women
included in all other large CAS trials (n  72; 28%) in the
endarterectomy vs angioplasty in patients with symptom-
atic severe carotid stenosis (EVA3S) and n  55 (33%) in
the Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) trial.17,18
In reality, women are severely under-represented in all
carotid trials (CEA andCAS trials) and it remains to be seen
whether sufficient enrollment of women will play a decisive
role in the ongoing trials analyzing CAS.21,22
The causes of perioperative gender risk difference in
CEA are not known. Due to the carotid small size and
women’s vessel anatomy, the surgical procedure may be
more problematic, and consequently, the incidence of ca-
rotid thrombosis and surgery-related complications in
women increases.23,24 CAS has the potential to avoid these
complications by using a completely different approach for
treating carotid stenosis. The carotid artery is not opened
and sutured, but the carotid flow is restored by using
appropriately sized stents.
In our study, although women in the CAS group had
small vessels, these did not increase the stroke risk or the
restenosis rate (1.8%) at 5 years. Conversely, in the CEA
group, the restenosis risk was higher (8.1%), although there
was a borderline difference when compared to CAS (P 
.058). In contrast with our data, the SPACE trial raised
concerns that the risk of restenosis might be two times higher
after CAS than after CEA, although the analysis was not
stratified by gender.20 However, today there is still large
variability and lack of standards to assess restenosis rates.
Criteria for measurements not uniform in stent vs no-stent
arteries, different thresholds, and ultrasound scan-subjec-
tive assessments make comparisons in restenosis rates
poorly reliable, and “restenosis” should be considered as a
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showing restenosis rates higher after CAS than after CEA
failed to show any increased late stroke risk after CAS
confirming an efficacy from CAS in stroke prevention,
which our study confirmed in women (low stroke rate after
CAS in the women in our study).
This study focused primarily on periprocedural risks,
since this has been recognized as themost hazardous period
of CEA for women with carotid stenosis. In the long term,
women, especially when asymptomatic, are believed to have
a very low stroke risk defeating any benefit provided from
early revascularization. However, the apparent small risk is
compensated by the higher survival of women. Stroke rate
increases with age in both genders; the longer the survival
times, the higher the risk of stroke. Late unpublished
data from the ACST study found that the risk of stroke
for women allocated to best medical treatment increased
at 10 years to 16% vs 10% in the surgical arm (CEA)
making the difference statistically relevant (P  .05) in
favor of surgery for women.25 For asymptomatic women
undergoing CAS, in whom the initial periprocedural risk
appears to be decreased, the long-term benefit might be
even higher.26
Study limitations. This study presents limitations.
First, this was not a randomized trial and was based on a
retrospective analysis of data leading to all well-known
population selection bias. Evident differences between the
entire CAS and CEA populations were adjusted using
multivariable analyses, but inevitably, some variables, and
especially procedural factors specific for each treatment
group, could not be accounted for. However, sensitivity
analyses were performed to adjust for these technical de-
tails, and a number of these technical confounders were
specifically tested in multivariable models stratified for
treatment group (CAS or CEA alone) showing an insignif-
icant effect on outcome.
Secondly, the results might be underpowered because
of no “a priori” power calculation. The relatively small
numbers of women could not exclude type II errors. Cau-
tion should be taken in interpretation of specific OR from
logistic regression analysis because the number of events
compared with the number of parameters in the model may
result in unstable estimates.
Thirdly, our results were obtained after a considerable
number of CAS procedures that allowed operators to
achieve a stable low complication rate. The same safe out-
come in women could not be ensured in other settings with
less experience in CAS.
Finally, patients were not compared to medically-
treated patients with carotid stenosis; therefore, it was
difficult to establish the superiority of gender-related CAS
treatment.
CONCLUSION
At this time, there is no evidence of a gender effect on
clinical outcome after CAS. The periprocedural risk of
stroke or death in women who underwent CAS is low
(1.9%), and the risk of further ipsilateral strokes after CAS isnot more than 0.4% per year (5-year ipsilateral and any
perioperative stroke/death rate, 4.1%). Asymptomatic
women, in whom a poor perioperative outcome is expected
after CEA, might benefit the most from CAS. Differences
in anatomy (eg, small vessel size) that increase the operative
risk in women during CEA may be overcome by a CAS
approach in the future.
CASmight be a primary choice for treatment of asymp-
tomatic carotid stenosis in women. However, further high-
level and high-powered studies are needed to confirm this
hypothesis.
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DrMarc Mitchell (Jackson, Miss). As I understand your data,
it demonstrates good results with both carotid endarterectomy and
carotid angioplasty and stenting in both men and women. I think
the data makes a strong argument that women benefit from carotid
interventions just as men do. On what basis do you conclude that
carotid angioplasty and stenting is superior to endarterectomy in
women?
Dr De Rango. Because there might be some women, as
asymptomatic women, who benefit less from carotid endarterec-
tomy and may better advantage from carotid angioplasty and
stenting. We did not find any difference in outcome between
genders after carotid endarterectomy when we analyzed women as
a whole. We did a subgroup comparison between genders stratified
by symptoms and, after carotid endarterectomy, and according to
our data, the risk of stroke in asymptomatic women was higher
than in asymptomatic men. On the contrary, there was no differ-
ence between genders in the perioperative and late stroke risk for
either asymptomatic or symptomatic subgroups of patients afterbe some subgroups of women who are still at high risk from
surgery and from carotid endarterectomy and could benefit from
stenting.
Dr Wei Zhou (Palo Alto, Calif). When we analyzed risk
factors for microemboli during carotid stenting, peripheral vascu-
lar disease was shown to be an independent predictor for contralat-
eral hemisphere subclinical microemboli. In your group, there
were many more patients with peripheral vascular diseases in the
male cohort than the female cohort. Would you please comment
on how this variable affected your outcome?
Dr De Rango. We did not find that the difference in distri-
bution of peripheral vascular disease affected outcome. Specifically,
in our multivariate analysis, there was no influence (“confounding
effect”) of peripheral disease on operative risks. We did not specif-
ically analyze outcome in the subgroup of patients with peripheral
disease who accounted for a small part of the overall population.
Multivariate analysis, however, failed to show an association be-
tween the presence of peripheral disease and the outcome.
